RAS and BRAF mutations in cell-free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue-tested RAS wild-type advanced colorectal cancer

EJ Helden; L (Lindsay) Angus; CW Menke-van der Houven van Oordt; DAM Heideman; E Boon; SC van Es; SA Radema; CML van Herpen; DJA de Groot; E G de Vries; Maurice Jansen; Stefan Sleijfer; HMW Verheul

doi:10.1002/1878-0261

RAS and BRAF mutations in cell-free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue-tested RAS wild-type advanced colorectal cancer

EJ Helden
, L (Lindsay) Angus
, CW Menke-van der Houven van Oordt
, DAM Heideman
, E Boon
, SC van Es
, SA Radema
, CML van Herpen
, DJA de Groot
, E G de Vries
, Maurice Jansen
, Stefan Sleijfer
, HMW Verheul

Medical Oncology

Research output: Contribution to journal › Article › Academic

39 Citations (Scopus)

Original language	Undefined/Unknown
Pages (from-to)	2361-2374
Number of pages	14
Journal	Molecular Oncology
Volume	13
Issue number	11
DOIs	https://doi.org/10.1002/1878-0261
Publication status	Published - 2019

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Research programs

EMC MM-03-86-01

Access to Document

10.1002/1878-0261

Cite this

Helden, EJ., Angus, L., Menke-van der Houven van Oordt, CW., Heideman, DAM., Boon, E., van Es, SC., Radema, SA., van Herpen, CML., de Groot, DJA., de Vries, E. G., Jansen, M., Sleijfer, S., & Verheul, HMW. (2019). RAS and BRAF mutations in cell-free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue-tested RAS wild-type advanced colorectal cancer. Molecular Oncology, 13(11), 2361-2374. https://doi.org/10.1002/1878-0261

@article{c43f409c9f6f4b5b916fbe4cfb972b6e,

title = "RAS and BRAF mutations in cell-free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue-tested RAS wild-type advanced colorectal cancer",

author = "EJ Helden and Angus, \{L (Lindsay)\} and \{Menke-van der Houven van Oordt\}, CW and DAM Heideman and E Boon and \{van Es\}, SC and SA Radema and \{van Herpen\}, CML and \{de Groot\}, DJA and \{de Vries\}, \{E G\} and Maurice Jansen and Stefan Sleijfer and HMW Verheul",

year = "2019",

doi = "10.1002/1878-0261",

language = "Undefined/Unknown",

volume = "13",

pages = "2361--2374",

journal = "Molecular Oncology",

issn = "1574-7891",

publisher = "John Wiley \& Sons Ltd.",

number = "11",

}

Helden, EJ, Angus, L, Menke-van der Houven van Oordt, CW, Heideman, DAM, Boon, E, van Es, SC, Radema, SA, van Herpen, CML, de Groot, DJA, de Vries, EG, Jansen, M , Sleijfer, S & Verheul, HMW 2019, 'RAS and BRAF mutations in cell-free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue-tested RAS wild-type advanced colorectal cancer', Molecular Oncology, vol. 13, no. 11, pp. 2361-2374. https://doi.org/10.1002/1878-0261

TY - JOUR

T1 - RAS and BRAF mutations in cell-free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue-tested RAS wild-type advanced colorectal cancer

AU - Helden, EJ

AU - Angus, L (Lindsay)

AU - Menke-van der Houven van Oordt, CW

AU - Heideman, DAM

AU - Boon, E

AU - van Es, SC

AU - Radema, SA

AU - van Herpen, CML

AU - de Groot, DJA

AU - de Vries, E G

AU - Jansen, Maurice

AU - Sleijfer, Stefan

AU - Verheul, HMW

PY - 2019

Y1 - 2019

U2 - 10.1002/1878-0261

DO - 10.1002/1878-0261

M3 - Article

SN - 1574-7891

VL - 13

SP - 2361

EP - 2374

JO - Molecular Oncology

JF - Molecular Oncology

IS - 11

ER -